Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Verrica Pharmaceuticals Inc
(NQ:
VRCA
)
6.690
-0.360 (-5.11%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
149,102
Open
7.080
Bid (Size)
6.850 (1)
Ask (Size)
7.120 (2)
Prev. Close
7.050
Today's Range
6.600 - 7.140
52wk Range
2.860 - 11.41
Shares Outstanding
41,957,197
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
7 Short-Squeeze Stocks That Could Beat Down the Bears
July 15, 2024
Panic can be a cruel emotion, especially when the consequences are uncapped red ink.
Via
InvestorPlace
Verrica Pharmaceuticals Announces Litigation Settlement with Dormer Laboratories, Inc.
July 01, 2024
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
Performance
YTD
-1.76%
-1.76%
1 Month
-15.85%
-15.85%
3 Month
-3.95%
-3.95%
6 Month
+18.41%
+18.41%
1 Year
+14.55%
+14.55%
More News
Read More
Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York
May 30, 2024
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
VERRICA ALERT: Bragar Eagel & Squire, P.C. is Investigating Verrica Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
May 26, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
Earnings Scheduled For February 29, 2024
February 29, 2024
Via
Benzinga
Earnings Outlook For Verrica Pharmaceuticals
February 28, 2024
Via
Benzinga
VERRICA ALERT: Bragar Eagel & Squire, P.C. is Investigating Verrica Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
May 17, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
Verrica Pharmaceuticals Announces Amendment to Company’s Collaboration and License Agreement with Torii Pharmaceutical Co. Ltd. to Fund Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts
May 15, 2024
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
Planet Fitness To Rally Around 19%? Here Are 10 Top Analyst Forecasts For Tuesday
May 14, 2024
Via
Benzinga
VRCA Stock Earnings: Verrica Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024
May 13, 2024
Via
InvestorPlace
Verrica Pharmaceuticals Reports First Quarter 2024 Financial Results
May 13, 2024
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
Verrica Pharmaceuticals to Present at Upcoming Investor Conferences
May 09, 2024
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
Verrica Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2024 Financial Results on May 13, 2024
May 08, 2024
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
Bragar Eagel & Squire is Investigating Certain Officers and Directors of Caribou, Verrica, and Playstudios on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
April 27, 2024
From
Bragar Eagel & Squire
Via
GlobeNewswire
Verrica Pharmaceuticals Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference
April 02, 2024
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
Verrica Pharmaceuticals Announces that YCANTH™ Receives New Chemical Entity Status and Orange Book Listing from the FDA
March 26, 2024
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
VERRICA PHARMACEUTICALS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Verrica Pharmaceuticals Inc. - VRCA
March 08, 2024
From
Kahn Swick & Foti, LLC
Via
Business Wire
Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results
February 29, 2024
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
Verrica Pharmaceuticals Announces Participation in the TD Cowen 44th Annual Healthcare Conference
February 27, 2024
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
Verrica Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full-Year 2023 Financial Results on February 29, 2024
February 22, 2024
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
VERRICA PHARMACEUTICALS INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Verrica Pharmaceuticals Inc. - VRCA
February 14, 2024
From
Kahn Swick & Foti, LLC
Via
Business Wire
Verrica Pharmaceuticals Files Lawsuit Against Canadian Drug Manufacturer for False Advertising and Unfair Competition
February 05, 2024
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
Verrica Pharmaceuticals Receives Permanent J-Code (J7354) for YCANTH™ from Centers for Medicare and Medicaid Services
January 29, 2024
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
7 Potential Short-Squeeze Stocks Poised for Rapid Gains
January 22, 2024
Via
InvestorPlace
Verrica Pharmaceuticals Announces Last Patient Dosed in Part 2 of Phase 2 Study of VP-315, a Potential First-in-Class Oncolytic Peptide-Based Immunotherapy, for the Treatment of Basal Cell Carcinoma
January 05, 2024
From
Verrica Pharmaceuticals Inc.
Via
GlobeNewswire
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.